摩根大通的Editas Medicine因最近的疲软而升级

2024-05-09 20:59

Following a ~11% drop in the wake of its Q1 2024 results, Editas Medicine (NASDAQ:EDIT) traded higher premarket Thursday after J.P. Morgan upgraded the gene editing drug developer, citing the stock’s recent underperformance.
EDIT has lost ~50% this year, while SPDR S&P Biotech ETF (XBI), which represents the broader biotech sector, has remained mostly flat.
“Editas has a systemic, modular approach that may allow for differentiation over competitors,” J.P. Morgan’s Terence Flynn wrote as he upgraded the stock to Equal Weight from Underweight, keeping his price target unchanged at $7 per share.
As the next catalyst for the stock, the analyst highlights mid-year data updates expected from the company’s RUBY and EdiTHAL clinical trials for gene-edited medicine reni-cel in severe sickle cell disease and transfusion-dependent beta-thalassemia.

More on Editas Medicine